In detail, for HepG2 cells, we found a reduction of hepatoma cell masses for the combinatorial setting down to 37.6% compared to 84.7% (resminostat alone) and 65.2% (MeV-SCD single-agent treatment). Here, SCD is linked to hepatocellular carcinoma.